We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » U.S. Fabry Patients Petition for Same Fabrazyme Preference as EU
U.S. Fabry Patients Petition for Same Fabrazyme Preference as EU
June 9, 2011
A group of U.S. patients with Fabry disease intensified their campaign to get an open license for Genzyme’s Fabrazyme during an ongoing shortage, citing preferential treatment of Fabry patients in Europe.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor